Philip Morris CEO Says Cigarettes Belong in a Museum as Zyn and IQOS Surge
Speakers
Summary
- Philip Morris International (PMI) is aggressively pivoting away from combustible cigarettes, with CEO Jacek Olczak stating cigarettes "belong in a museum."
- "Smoke-free" products (Zyn and IQOS) now account for roughly 40% of PMI's total revenue, with IQOS revenue specifically surpassing Marlboro revenue.
- Global Zyn shipments are projected to more than double from 421 million cans in 2023 to an estimated 1 billion in 2026.
- The "nicotine profit pool" is expanding despite declining smoking rates, driven by new delivery mechanisms (pouches/heat-not-burn) that allow for discreet, white-collar usage.
- PMI is localizing supply chains, breaking ground on a new manufacturing facility in Aurora, Colorado (Dec 2024) to serve the US market.
Trade Ideas
"By 2030, we should have a total of the revenues coming from this product [smoke-free]." Additionally, "IQOS today's revenue is larger than Marlboro" and Zyn shipments are predicted to hit 1 billion in 2026. PMI has successfully executed a "self-disruption" strategy. By acquiring Swedish Match (Zyn) and developing IQOS, they have immunized themselves against the secular decline of smoking. They are capturing a new demographic (white-collar workers) who would never smoke cigarettes but will use discreet pouches. The construction of the Colorado facility indicates massive demand and a move to secure US market share against competitors like Altria. Long PM as the clear winner in the "Nicotine 2.0" transition, offering growth (Zyn) and stability (legacy pricing power) with a valuation that may re-rate higher as it becomes less of a "sin stock" and more of a consumer packaged goods (CPG) play. Regulatory crackdown on flavored pouches (similar to vaping bans); long-term health studies revealing cardiovascular risks associated with high-concentration nicotine pouches.
"Zyn... is by far the biggest winner in the roughly 20 billion dollars oral tobacco market." While the video focuses on PMI's success, this implies a direct threat to competitors. Altria (MO) and British American Tobacco (BTI) have competing products (on! and Velo/Vuse), but Zyn is described as the "superior product" with dominant brand equity ("Zyn is not a sin"). If PMI is winning the growth war in oral nicotine, legacy competitors are at risk of losing the only growing segment of the industry. Watch these tickers for market share erosion. If Zyn continues to dominate the US market via the new Colorado facility, MO and BTI face an existential growth crisis. Competitors could slash prices to defend market share, triggering a margin-crushing price war.
Up Next
This Bloomberg Markets video, published March 08, 2026, features Jacek Olczak, Ken Shea discussing PM, MO, BTI. 2 trade ideas extracted by AI with direction and confidence scoring.
Speakers: Jacek Olczak, Ken Shea · Tickers: PM, MO, BTI